Abstract
P-Glycoprotein (Pgp) and cytochrome P450 3A (CYP3A) are important enzymes affecting the disposition of HIV protease inhibitors (HIV PIs). After multiple dosing experiments in rats, decreases in the plasma concentrations and area under plasma concentration-time curve (AUC) for HIV PIs have been observed. The purpose of these studies was to determine the changes in Pgp and CYP3A expression and HIV PI plasma exposure after multiple doses of HIV PIs. Male rats were orally dosed with an amprenavir prodrug (450 mg/kg/day amprenavir-equivalent) or nelfinavir (175 mg/kg/day) for 1 or 14 days. Relative to day 1, theCmax and the AUC for amprenavir at day 14 were decreased by 33 and 51%, respectively. Similarly, the plasma concentration of nelfinavir at 1 h after the last dose (Cmax) was reduced by 52% after multiple doses. Compared with controls, dosing of amprenavir for 14 days increased intestinal Pgp and hepatic CYP3A protein levels by 59 and 151%, respectively, but did not alter intestinal CYP3A protein levels. In contrast, amprenavir treatment did not result in an increase in hepatic CYP3A activity. Nelfinavir treatment increased expression of intestinal Pgp and hepatic CYP3A levels by 83 and 85%, respectively, but not hepatic Pgp or intestinal CYP3A. HIV PIs also induced Pgp expression in the LS174T human intestinal cell line. These results indicate that HIV protease inhibitors induce both intestinal Pgp and hepatic CYP3A and suggest that induction of Pgp and CYP3A is a possible mechanism reducing drug exposure after multiple doses.
Footnotes
-
Send reprint requests to: Dr. Joseph W. Polli, Bioanalysis and Drug Metabolism, Glaxo SmithKline, Inc., Rm. MAI.A3666, P.O. Box 13398, Research Triangle Park, NC 27709-3398. E-mail:JP16063{at}glaxowellcome.com
- Abbreviations used are::
- Pgp
- P-glycoprotein
- AUC
- area under plasma concentration-time curve
- BBM
- brush border membrane
- CYP3A
- cytochrome P450 3A
- HIV PI
- human immunodeficiency virus protease inhibitor
- P450
- cytochrome P450
- HPMC
- hydroxypropylmethylcellulose
- PMSF
- phenylmethylsulfonyl fluoride
- HPLC
- high-performance liquid chromatography
- LC/MS/MS
- liquid chromatography tandem mass spectrometry
- MDR
- multidrug resistance
- DMSO
- dimethyl sulfoxide
- Received August 14, 2000.
- Accepted January 19, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|